- Home
- Publications
- Publication Search
- Publication Details
Title
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-10-28
DOI
10.3389/fphar.2021.754239
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antagonistic effects of finerenone and spironolactone on the aldosterone‐regulated transcriptome of human kidney cells
- (2021) Florian Le Billan et al. FASEB JOURNAL
- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- (2021) Suetonia C Palmer et al. BMJ-British Medical Journal
- Treatment of Diabetic Kidney Disease: Current and Future
- (2021) Tomotaka Yamazaki et al. Diabetes & Metabolism Journal
- Finerenone Reduces Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2021) Gerasimos Filippatos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy
- (2021) Swayam Prakash Srivastava et al. Nature Communications
- Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
- (2021) Peter Kolkhof et al. AMERICAN JOURNAL OF NEPHROLOGY
- Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study
- (2021) Sadayoshi Ito et al. Clinical and Experimental Nephrology
- Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study
- (2021) Takeshi Okanoue et al. HEPATOLOGY RESEARCH
- Activation of Rac1-Mineralocorticoid Receptor Pathway Contributes to Renal Injury in Salt-Loaded db/db Mice
- (2021) Daigoro Hirohama et al. HYPERTENSION
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus
- (2021) Swayam Prakash Srivastava et al. Journal of the American Heart Association
- The Role of Finerenone in the Management of Diabetic Nephropathy
- (2021) Stavroula Veneti et al. Diabetes Therapy
- Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
- (2021) Nina Vodošek Hojs et al. Pharmaceuticals
- Aldosterone Inhibits In Vitro Myogenesis by Increasing Intracellular Oxidative Stress via Mineralocorticoid Receptor
- (2021) Jin Young Lee et al. Endocrinology and Metabolism
- Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
- (2021) Peter Rossing et al. DIABETES OBESITY & METABOLISM
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- (2021) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- Crystal structure of the mineralocorticoid receptor ligand‐binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS‐3150)
- (2020) Mizuki Takahashi et al. FEBS LETTERS
- Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
- (2020) Nete Tofte et al. Lancet Diabetes & Endocrinology
- Non‐steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease
- (2020) Omar Al Dhaybi et al. DIABETES OBESITY & METABOLISM
- Effect of Angiotensin II on ENaC in the Distal Convoluted Tubule and in the Cortical Collecting Duct of Mineralocorticoid Receptor Deficient Mice
- (2020) Peng Wu et al. Journal of the American Heart Association
- Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker
- (2020) Kiyoshi Arai et al. HYPERTENSION RESEARCH
- Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease
- (2020) Ningning Wan et al. JOURNAL OF HUMAN HYPERTENSION
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy
- (2020) Mostafa El Mokadem et al. CardioRenal Medicine
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Non-coding RNAs and the mineralocorticoid receptor in the kidney
- (2020) Michael B. Butterworth MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice
- (2019) Abdus Sattar Bhuiyan et al. HYPERTENSION RESEARCH
- Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes
- (2019) Dan Dong et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Corticosteroids and Regional Variations in Thickness of the Human Cerebral Cortex across the Lifespan
- (2019) Nadine Parker et al. CEREBRAL CORTEX
- Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
- (2019) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Mitigating risk of aldosterone in diabetic kidney disease
- (2019) Marie Frimodt-Møller et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- (2019) Sadayoshi Ito et al. HYPERTENSION
- Independent regulation of renin–angiotensin–aldosterone system in the kidney
- (2018) Akira Nishiyama et al. Clinical and Experimental Nephrology
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling
- (2018) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology
- (2018) Steven J. Forrester et al. PHYSIOLOGICAL REVIEWS
- Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats
- (2018) Lei Li et al. HYPERTENSION RESEARCH
- Novel Insights into the Crosstalk between Mineralocorticoid Receptor and G Protein-Coupled Receptors in Heart Adverse Remodeling and Disease
- (2018) Barbara Parker et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Endothelial Mineralocorticoid Receptor Mediates Parenchymal Arteriole and Posterior Cerebral Artery Remodeling During Angiotensin II–Induced HypertensionNovelty and Significance
- (2017) Janice M. Diaz-Otero et al. HYPERTENSION
- Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance
- (2017) Lionel Lattenist et al. HYPERTENSION
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor null mice: informing cell-type-specific roles
- (2017) Timothy J Cole et al. JOURNAL OF ENDOCRINOLOGY
- Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1
- (2017) Jonatan Barrera-Chimal et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- AT2 receptors in cardiovascular and renal diseases
- (2017) Elena Kaschina et al. PHARMACOLOGICAL RESEARCH
- Aldosterone signaling regulates the over-expression of claudin-4 and -8 at the distal nephron from type 1 diabetic rats
- (2017) Eduardo Molina-Jijón et al. PLoS One
- Spironolactone promotes autophagy via inhibiting PI3K/AKT/mTOR signalling pathway and reduce adhesive capacity damage in podocytes under mechanical stress
- (2016) D. Li et al. BIOSCIENCE REPORTS
- Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences
- (2016) Jun Yang et al. CURRENT OPINION IN PHARMACOLOGY
- JAK inhibition in the treatment of diabetic kidney disease
- (2016) Frank C. Brosius et al. DIABETOLOGIA
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies
- (2016) Silvia Lentini et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy
- (2016) Jana Grune et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials
- (2016) Jie V. Zhao et al. Journal of the American Society of Hypertension
- Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review
- (2016) F. Persson et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
- (2016) Gemma Currie et al. BMC Nephrology
- Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena
- (2016) Murray Epstein Kidney International Supplements
- Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial
- (2015) Sawako Kato et al. Clinical and Experimental Nephrology
- Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease
- (2015) Andrew S. Brem et al. CLINICAL SCIENCE
- Angiotensin-(1–7) prevents systemic hypertension, attenuates oxidative stress and tubulointerstitial fibrosis, and normalizes renal angiotensin-converting enzyme 2 and Mas receptor expression in diabetic mice
- (2015) Yixuan Shi et al. CLINICAL SCIENCE
- Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis
- (2015) Jing Hou et al. CLINICAL THERAPEUTICS
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Spironolactone inhibits podocyte motility via decreasing integrin β1 and increasing integrin β3 in podocytes under high-glucose conditions
- (2015) ZHUO LI et al. Molecular Medicine Reports
- Diabetic Kidney Disease: A Report From an ADA Consensus Conference
- (2014) Katherine R. Tuttle et al. DIABETES CARE
- Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats
- (2014) Amal Hofni et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Detailed Localization of Augmented Angiotensinogen mRNA and Protein in Proximal Tubule Segments of Diabetic Kidneys in Rats and Humans
- (2014) Masumi Kamiyama et al. International Journal of Biological Sciences
- The Mineralocorticoid Receptor Promotes Fibrotic Remodeling in Atrial Fibrillation
- (2014) Daniel Lavall et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Local Mineralocorticoid Receptor Activation and the Role of Rac1 in Obesity-Related Diabetic Kidney Disease
- (2014) Shigetaka Yoshida et al. NEPHRON EXPERIMENTAL NEPHROLOGY
- Mineralocorticoid Receptor Phosphorylation Regulates Ligand Binding and Renal Response to Volume Depletion and Hyperkalemia
- (2013) Shigeru Shibata et al. Cell Metabolism
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms
- (2013) Dong Chen et al. GENE
- Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injury
- (2013) Simone M. Blattner et al. KIDNEY INTERNATIONAL
- Spironolactone inhibits apoptosis in rat mesangial cells under hyperglycaemic conditions via the Wnt signalling pathway
- (2013) Dan Zhu et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial
- (2013) A. Esteghamati et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Oxidative Stress Causes Mineralocorticoid Receptor Activation in Rat Cardiomyocytes
- (2012) Miki Nagase et al. HYPERTENSION
- Aldosterone Induces Kidney Fibroblast Proliferation via Activation of Growth Factor Receptors and PI3K/MAPK Signalling
- (2012) L.L. Huang et al. NEPHRON EXPERIMENTAL NEPHROLOGY
- ACE2, angiotensin-(1–7), and Mas: the other side of the coin
- (2012) Michael Bader PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- NADPH oxidase-mediated Rac1 GTP activity is necessary for nongenomic actions of the mineralocorticoid receptor in the CA1 region of the rat hippocampus
- (2011) Fumiko Kawakami-Mori et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells
- (2011) Tetsuo Nishikawa et al. ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
- Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?
- (2011) Louise A. Burton et al. CLINICAL ENDOCRINOLOGY
- Aldosterone promotes atrial fibrillation
- (2011) Jan-Christian Reil et al. EUROPEAN HEART JOURNAL
- Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor–dependent pathway
- (2011) Shigeru Shibata et al. JOURNAL OF CLINICAL INVESTIGATION
- The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease
- (2011) Nobuo Tsuboi et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Acute and chronic regulation of aldosterone production
- (2011) Namita G. Hattangady et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease
- (2011) M. Lian et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production
- (2011) J. Toyonaga et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effects of Spironolactone and Losartan on Diabetic Nephropathy in a Type 2 Diabetic Rat Model
- (2011) Mi Young Lee et al. Diabetes & Metabolism Journal
- Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure
- (2010) Masayuki Yamaji et al. AMERICAN HEART JOURNAL
- Minireview: Aldosterone and Mineralocorticoid Receptors: Past, Present, and Future
- (2010) John W. Funder ENDOCRINOLOGY
- Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species—ERK/JNK pathways
- (2010) Naro Ohashi et al. HYPERTENSION RESEARCH
- Involvement of mineralocorticoid receptor in high glucose-induced big mitogen-activated protein kinase 1 activation and mesangial cell proliferation
- (2010) Gang Liu et al. JOURNAL OF HYPERTENSION
- Spironolactone ameliorates podocytic adhesive capacity via restoring integrin α3 expression in streptozotocin-induced diabetic rats
- (2010) Shan Lin et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Serum- and glucocorticoid-regulated kinase 1 is upregulated following unilateral ureteral obstruction causing epithelial–mesenchymal transition
- (2010) Jizhong Cheng et al. KIDNEY INTERNATIONAL
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mineralocorticoid Receptor Blockade Enhances the Antiproteinuric Effect of an Angiotensin II Blocker through Inhibiting Podocyte Injury in Type 2 Diabetic Rats
- (2009) A. Nishiyama et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
- (2009) U. F. Mehdi et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Spironolactone exhibits direct renoprotective effects and inhibits renal renin–angiotensin–aldosterone system in diabetic rats
- (2008) Masateru Taira et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats
- (2008) Helmy M. Siragy et al. EXPERIMENTAL PHYSIOLOGY
- Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease
- (2008) Shigeru Shibata et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now